Pricing
  1. JP-listed companies
  3. Financials
  4. Pretax margin (%)

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Dec 31, 2025-731.9+150.00%
Dec 31, 2024-292.8-90.71%
Dec 31, 2023-3,151.1+68.52%
Dec 31, 2022-1,869.8-85.47%
Dec 31, 2021-12,865.5+1184.75%
Dec 31, 2020-1,001.4+4.15%
Dec 31, 2019-961.5-93.72%
Dec 31, 2018-15,303.6+2967.53%
Dec 31, 2017-498.9-91.43%
Dec 31, 2016-5,824.7+121.07%
Dec 31, 2015-2,634.7-31.58%
Dec 31, 2014-3,850.5+328.21%
Dec 31, 2013-899.2+36.52%
Dec 31, 2012-658.7+918.20%
Dec 31, 2011-64.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat